Mitchell Sinkler & Starr PA Makes New $240,000 Investment in Edwards Lifesciences Co. (NYSE:EW)

Mitchell Sinkler & Starr PA purchased a new stake in shares of Edwards Lifesciences Co. (NYSE:EW) during the second quarter, HoldingsChannel.com reports. The institutional investor purchased 2,800 shares of the medical research company’s stock, valued at approximately $240,000.

A number of other hedge funds also recently made changes to their positions in the business. HHM Wealth Advisors LLC bought a new stake in shares of Edwards Lifesciences during the second quarter valued at approximately $55,000. Coldstream Capital Management Inc. raised its holdings in shares of Edwards Lifesciences by 3.8% during the second quarter. Coldstream Capital Management Inc. now owns 8,163 shares of the medical research company’s stock valued at $754,000 after buying an additional 302 shares during the last quarter. Daiwa Securities Group Inc. raised its holdings in shares of Edwards Lifesciences by 20.0% during the second quarter. Daiwa Securities Group Inc. now owns 88,748 shares of the medical research company’s stock valued at $8,197,000 after buying an additional 14,768 shares during the last quarter. Chesapeake Capital Corp IL bought a new stake in shares of Edwards Lifesciences during the second quarter valued at approximately $559,000. Finally, Andra AP fonden raised its holdings in shares of Edwards Lifesciences by 125.9% during the second quarter. Andra AP fonden now owns 83,800 shares of the medical research company’s stock valued at $7,741,000 after buying an additional 46,700 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Up 1.7 %

NYSE EW opened at $68.25 on Thursday. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71. The stock has a market cap of $41.11 billion, a price-to-earnings ratio of 29.42, a PEG ratio of 2.79 and a beta of 1.13. The firm’s 50 day moving average price is $73.32 and its two-hundred day moving average price is $83.72.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. The firm had revenue of $1.63 billion for the quarter, compared to analysts’ expectations of $1.65 billion. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The company’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.66 EPS. Equities analysts anticipate that Edwards Lifesciences Co. will post 2.7 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $93.29, for a total transaction of $466,450.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $4,378,659.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the sale, the vice president now owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $93.29, for a total transaction of $466,450.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $4,378,659.44. The disclosure for this sale can be found here. Insiders sold 16,250 shares of company stock valued at $1,218,138 in the last quarter. Company insiders own 1.29% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on EW shares. Baird R W lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 25th. StockNews.com lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Thursday, July 25th. UBS Group lowered their price objective on shares of Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating on the stock in a research note on Tuesday. The Goldman Sachs Group lowered their price objective on shares of Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating on the stock in a research note on Friday, July 26th. Finally, Canaccord Genuity Group lowered their price objective on shares of Edwards Lifesciences from $85.00 to $77.00 and set a “hold” rating on the stock in a research note on Thursday, July 25th. Fifteen research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $80.81.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.